Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy

Phase 3 Completed 654 enrolled GBG Forschungs GmbH Austrian Breast & Colorectal Cancer Study Group · collab Novartis Pharmaceuticals · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the event-free survival (EFS) after zoledronic acid for 5 years versus no postoperative treatment in patients with "chemo-insensitive" breast cancer (ypT1-4 and/or ypN1-3) after preoperative anthracycline/taxane containing chemotherapy

Timeline

Start: 2004-12
Primary completion: 2013-11
Completion: 2013-11

Publications

Adams A, Jakob T, Huth A, Monsef I, Ernst M, Kopp M, Caro-Valenzuela J, Wockel A, Skoetz N. Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis. Cochrane Database Syst Rev. 2024 Jul 9;7(7):CD013451. doi: 10.1002/14651858.CD013451.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Zoledronic acid	Other / unclassified	4 mg	Other

Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy

Summary

Timeline

Publications

Drugs

Indications